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Juanes et al. show that EB1, a key
regulator of microtubule dynamics,
directly inhibits APC-mediated actin
assembly in vitro and governs APC-
dependent cellular F-actin levels and
directed cell migration. These results
suggest that EB1 promotes bidirectional
cytoskeletal crosstalk by coordinating
microtubule and actin dynamics..
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https://doi.org/10.1016/j.cub.2020.08.094SUMMARYEB1 was discovered 25 years ago as a binding partner of the tumor suppressor adenomatous polyposis coli
(APC) [1]; however, the significance of EB1-APC interactions has remained poorly understood. EB1 functions
at the center of a network of microtubule end-tracking proteins (+TIPs) [2–5], and APC binding to EB1 pro-
motes EB1 association with microtubule ends and microtubule stabilization [6, 7]. Whether EB1 interactions
govern functions of APC beyondmicrotubule regulation has not been explored. The C-terminal basic domain
of APC (APC-B) directly nucleates actin assembly, and this activity is required in vivo for directed cell migra-
tion and for maintaining normal levels of F-actin [8–10]. Here, we show that EB1 binds APC-B and inhibits its
actin nucleation function by blocking actin monomer recruitment. Consistent with these biochemical obser-
vations, knocking down EB1 increases F-actin levels in cells, and this can be rescued by disrupting APC-
mediated actin nucleation. Conversely, overexpressing EB1 decreases F-actin levels and impairs directed
cell migration without altering microtubule organization and independent of its direct binding interactions
with microtubules. Overall, our results define a new function for EB1 in negatively regulating APC-mediated
actin assembly. Combining these findings with other recent studies showing that APC interactions regulate
EB1-dependent effects on microtubule dynamics [7], we propose that EB1-APC interactions govern bidirec-
tional cytoskeletal crosstalk by coordinating microtubule and actin dynamics.RESULTS AND DISCUSSION
EB1 Directly Inhibits APC-Mediated Actin Nucleation
In Vitro
EB1 is amaster regulator of themicrotubule end-tracking protein
(+TIP) interaction network, tracking the growing plus ends of mi-
crotubules and recruiting other microtubule-associated proteins
(MAPs) to microtubule ends [2–5]. EB1 dimers bind to microtu-
bules using calponin homology (CH) domains and have EEY/F
motifs that bind proteins with cytoskeleton-associated protein
glycine-rich (CAP-Gly) domains and an end-binding homology
(EBH) domain that binds proteins with SxIP motifs (where x is
any residue) [11–13] (Figure 1A). More recently, EB1 has been
shown to bind LxxPTPh motifs (where x is any residue, and h
is any hydrophobic residue) [12] (Figure 1A). Notably, adenoma-
tous polyposis coli (APC) contains two previously described
SxIP motifs, one located in its basic domain (APC-B) and one
in its flanking C-terminal domain [11, 14] (see asterisks in the
schematic in Figure 1B). Mutating both SxIP motifs strongly re-
duces EB1 recruitment of APC to microtubule plus ends
in vitro [7]; however, it has remained unclear whether these
SxIP mutations disrupt all interactions of EB1 with APC, which
we address below.
In previous studies, we showed that APC-B potently nucleates
actin assembly in vitro by dimerizing and recruiting actinCurrent Biology 30, 1–10, D
This is an open access article under the CC BY-Nmonomers to seed polymerization and that this activity is critical
for maintaining normal F-actin levels in cells and for directed cell
migration [15, 16]. Here we investigated whether EB1might influ-
ence the actin assembly functions of APC. We first tested the
in vitro effects of full-length EB1 on the actin nucleation activities
of APC-B as well as a longer APC-C construct (Figure 1B) [17–
19]. In bulk assays, EB1 inhibited the nucleation activity of 20-
nM APC-B and APC-C in a dose-dependent manner (Figure 1C;
Figure S1A). EB1 also strongly inhibited the collaborative actin
assembly effects of APC and the formin Daam1 (Figure S1B). To-
tal internal reflection fluorescence (TIRF) microscopy was used
to directly observe actin filaments and verify EB1 inhibition of
APC (Figures 1D and 1E; Video S1). The inhibitory effects of
EB1 were more potent on APC-C than APC-B, consistent with
the presence of the extra SxIPmotif in APC-C, which presumably
leads to stronger EB1 binding (see below).
We next asked whether EB1 inhibition of APC-mediated actin
nucleation is dependent on the two SxIP motifs required for
APC’s ability to promote EB1 interactions with microtubules
[7]. One of the two SxIP motifs is missing in APC-B; therefore,
we targeted the remaining motif (SRLP) in APC-B, changing it
to LRDP as in Serre et al. [7]. The resulting mutant, APC-BLRDP
(S2537L, L2539D), was substantially less active in nucleating
actin assembly compared with wild-type APC-B (Figure S1C).








Figure 1. EB1 Directly Inhibits APC-Mediated Actin Nucleation In Vitro by Blocking APC-Actin Monomer Interactions
(A) Schematic of EB1 domains and interactions.
(B) Schematic of APC domains and interactions and APC polypeptides used in this study: APC-C (residues 2,130–2,843) and APC-B (residues 2,167–2,674).
Asterisks, SxIP motifs.
(C) Bulk actin assembly assays containing 2 mM G-actin (5% pyrene labeled), 5 mM profilin, and other ingredients as indicated.
(D) Representative images captured 1,125 s after initiation of actin assembly in TIRF assays. Reactions contain 1 mMG-actin (10% Oregon green labeled, 0.2%
biotin labeled), 5 mM profilin, +/ 1 nM APC-B, +/ 500 nM EB1. Scale bar, 15 mm.
(E) Average number of actin filaments per field of view (FOV) in TIRF assays as in (D). Data are averaged from three independent experiments (two FOVs per
experiment). Error bars, SD. One-way ANOVA, Holm-Sidak’s multiple comparison test. Statistical differences: **p < 0.01; n.s., not significant.
(legend continued on next page)
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Report(ANS2) region of the APC basic domain, which is required for
actin nucleation and mediates APC-B dimerization [15, 16].
Thus, mutating SRLP may reduce nucleation activity by weak-
ening dimerization. Using a higher concentration of APC-BLRDP
(400 nM), we could reach a nucleation activity equivalent to
20 nM wild-type APC-B and, under these conditions, still
observed strong inhibition by EB1 (Figure 1F). These results sug-
gest that the SRLP motif does not mediate key molecular inter-
actions underlying EB1 inhibition of APC-B.
We also used single-molecule imaging to compare binding of
labeled EB1 molecules to immobilized fluorescently labeled
APC-C, APC-B, and APC-BLRDP molecules, which were tagged
with modified O6-alkylguanine-DNA alkyl-transferase (AGT),
also known as SNAP-tag (for details regarding specificity and
saturation of binding, see STAR Methods). Importantly, SNAP-
labeled and unlabeled APC-B had similar effects in actin assem-
bly assays (Figure S1D). Untagged EB1 was directly labeled on a
single surface-exposed residue (Cys39) in its CH domain, which
did not interfere with its inhibition of APC-mediated actin nucle-
ation (Figure S1E). EB1 interactions with APC-C were stronger
than its interactions with APC-B, and EB1 still interacted with
APC-B when it carried the APC-BLRDP mutation (Figures 1G
and 1H). Together, these results show that the SxIP motifs
shown previously to be important for APC’s effects on EB1 bind-
ing to microtubules [7] are distinct from the interactions that un-
derlie EB1’s inhibitory effects on APC-B’s actin nucleation activ-
ity. Because APC-B does not contain any known EB1-binding
elements (CAP-Gly domains or LxxPTPh motifs), its inhibition
by EB1 may involve a novel type of molecular interaction that
has not yet been characterized.
EB1 Inhibits Actin Monomer Recruitment by APC-B
To better understand how EB1 inhibits APC-mediated actin
nucleation, we wanted to find out whether EB1 disrupts APC-B
interactions with actin monomers, a requirement for nucleation
[18, 19]. We used a binding assay in which APC-B increases
the fluorescence of pyrene-G-actin in a concentration-depen-
dent manner [18], reasoning that EB1 binding to APC may
reverse APC’s effect on pyrene-G-actin fluorescence. Indeed,
EB1 inhibited binding of APC-B to G-actin in a concentration-
dependent manner, with half-maximal effects at 300 nM EB1
(Figures 1I and 1J), and EB1 alone had little effect on pyrene-(F) Bulk actin assembly assays containing 2 mM G-actin (5% pyrene labeled), 5 m
(G) Representative images from single-molecule colocalization assays. 25 pM Bio
with 500 nM 594-labeled EB1, was incubated and then flowed into the chamber.
surface-anchored Biotin-649-APC molecules. Scale bar, 10 mm.
(H) Analysis of assays as in (G), quantifying the fraction of Biotin-anchored 649-SN
from six independent experiments for APC-B and seven for APC-C and APC-BLRD
spots per condition). Error bars, SD. Statistical significance was calculated by o
(I) G-actin binding assays in which the fluorescence of 100 nM latrunculin-B (La
contain 5 mM profilin (as in actin assembly assays in C and F) and other ingredie
Holm-Sidak’s t test: ***p < 0.001, n.s., not significant.
(J) Concentration-dependent effects of EB1 on APC-B binding to G-actin in assa
(K and L) Quantitative western blots used to determine the concentrations of en
sentative blot (from three independent trials) probed with anti-EB1 antibodies (K) o
cell lysate lane with known quantities of purified EB1 or APC-C proteins. Standard
of EB1 (201, 200, and 273 nM) and APC (7.5, 6.9, and 6.5 nM) were determined from
225 nM; APC, 7 nM).
See also Figure S1 and Video S1.G-actin fluorescence (Figure 1J). These assays were performed
in the presence of profilin because profilin was present in our
actin assembly assays. Profilin does not interfere with APC bind-
ing to G-actin [18]. Together, these observations suggest that
EB1 disrupts interactions between APC-B and G-actin to block
actin nucleation.
To determine whether the concentrations of EB1 that inhibit
APC are in the physiological range, we determined EB1 and
APC concentrations in U2OS osteosarcoma cells by quantitative
western blotting. The mean and SD from three experiments was
224.90 nM ± 41.96 for EB1 (Figure 1K) and 6.95 nM ± 0.50 for
APC in U2OS cells (Figure 1L). These concentrations in U2OS
cells are similar to the concentrations of EB1 and APC reported
for other cell lines [20, 21]. Thus, the inhibitory effects of EB1 on
APC that we observe in vitro occur in a physiologically relevant
concentration range.
EB1 Regulates APC-Dependent F-actin Levels in Cells
Previously we showed that APC-mediated actin nucleation is
required to maintain normal F-actin levels in U2OS cells [15].
Given our in vitro observations above, we analyzed the effects
of knocking down or overexpressing EB1 on cellular F-actin
levels. Western blotting confirmed EB1 silencing, rescue expres-
sion, and overexpression (Figure 2A). Cellular F-actin density (in-
tensity per unit cell area) was quantified by Alexa 568-phalloidin
staining (representative cell images in Figure 2B; see also Fig-
ure S2A; quantification in Figure 2C). There was no significant
difference in the mean cell area for any of the compared condi-
tions; thus, a change in average F-actin density corresponds to
a change in total F-actin levels. Consistent with our in vitro obser-
vations, EB1 knockdown led to a substantial increase in F-actin
density, and these defects were rescued by expression of RNAi-
refractive EB1-GFP at endogenous levels (Figures 2A–2C; Fig-
ure S2A). Conversely, EB1-GFP overexpression led to a
decrease in F-actin density, similar to cells expressing the nucle-
ation-impaired APC-m4 mutant [15, 16]. Similar results were
obtained when cells were fixed by an alternative method that en-
hances preservation of the actin cytoskeleton (Figures S2B and
S2C) [22]. Thus, EB1 negatively regulates F-actin levels in cells.
At least some of the effects of EB1 silencing on cellular F-actin
levels was due to an increase in stress fibers, as indicated by
alpha-actinin immunostaining (Figures S2D and S2E). AsM profilin, and other ingredients as indicated.
tin-649-labeled SNAP-APC-C, SNAP-APC-B, or SNAP-APC-BLRDP, without or
Yellow arrowheads indicate examples of 594-EB1 molecules colocalizing with
AP-APCmolecules that showed colocalization of 594-EB1. Data are averaged
P. 10 FOVs were analyzed per condition per experiment (in total, n > 5,000 APC
ne-way ANOVA, Holm-Sidak’s t test: **p < 0.01, n.s., not significant.
tB)-bound pyrene-actin monomers increases upon APC-B binding. Reactions
nts as indicated. Statistical significance was calculated by one-way ANOVA,
ys as in (I).
dogenous EB1 and APC proteins in U2OS cells. Each panel shows a repre-
r anti-APC antibodies (L), comparing the endogenous EB1 or APC signal in the
curves generated from each blot are shown below. The cellular concentrations
each of the three independent blots (STARMethods) and then averaged (EB1,






Figure 2. EB1 Regulates APC-Dependent F-actin Levels in Cells
(A) Representative western blots (from three independent blots) showing EB1 and EB1-GFP levels in whole-cell extracts fromU2OS cells: untreatedWT (Control),
mock-treated (scramble), EB1 knockdown (si-EB1; 96% depletion), knockdown and rescue by RNAi-refractive EB1-GFP (99% depletion, 1.4-fold higher level
than endogenous EB1), and overexpression of EB1-GFP (OE-EB1; 3.4-fold higher level). Blots were probed with antibodies to EB1 and Glyceraldehyde 3-
phosphate dehydrogenase (GADPH, loading control). The asterisk marks an extra band, likely from degradation of GFP-EB1. The expression levels stated above
represent the means from three independent experiments.
(B) Representative images of F-actin organization (Alexa 568-phalloidin staining) in cells as in (A) and cells expressing the APC-m4 mutant, which is impaired in
actin nucleation. Scale bar, 25 mm.
(C) Quantification of F-actin levels in cells. Box-and-whisker plots represent the mean and 10–90 percentile values for F-actin density (intensity over cell area) per
cell, measured from images as in (B). Data are averaged from three independent experiments (left to right: n = 55, 33, 63, 49, and 42 cells). The red dotted line
indicates the mean from control cells. Statistical significance was calculated by one-way ANOVA, Holm-Sidak’s t test: ****p < 0.0001, n.s., not significant.
(legend continued on next page)
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Reportreported previously [15, 16], APC silencing led to a decrease in
stress fiber levels.
To determine whether EB1’s effects on F-actin levels in cells
are APC-dependent, we wanted to find out whether they could
be suppressed by depletion of APC or by expression of APC-
m4. Western blotting confirmed APC and EB1 silencing and/or
expression of APC-m4 (Figure 2D). Analysis of F-actin density
showed that APC silencing or expression of APC-m4 sup-
pressed EB1 knockdown effects (representative cell images in
Figure 2E; see also Figure S2F; quantification in Figure 2F).
These results support a model in which EB1 negatively regulates
APC-mediated actin assembly in cells.
EB1 Regulates F-actin Levels in Cells Independent of Its
Direct Binding Interactions with Microtubules and F-
actin
We next considered whether the defects on cellular F-actin
levels caused by altering EB1 levels might stem from EB1’s
direct interactions with microtubules and/or F-actin. Therefore,
we compared the effects of overexpressing GFP-tagged EB1
wild type (EB1WT), EB1Q102E (which disrupts EB1 binding to mi-
crotubules), and EB1K89E (which disrupts EB1 binding to micro-
tubules and F-actin) [23, 24]. Overexpression was confirmed by
western blotting (Figure 3A). Both EB1 mutants reduced F-actin
density in cells, similar to EB1WT (Figures 3B and 3C; Figure S3).
Further, overexpression of EB1WT, EB1Q102E, and EB1K89E did
not alter microtubule organization or microtubule levels at the
cell periphery (Figures 3B and 3D; Figure S3). Consistent with
previous studies [15, 25], APC silencing led to a strong reduction
in peripheral microtubule staining whereas APC-m4 expression
did not. Thus, even though silencing EB1 alters microtubule or-
ganization [25–27], overexpression of EB1 does not, but it re-
duces F-actin levels. However, these effects on F-actin caused
by EB1 overexpression do not depend on its direct interactions
with microtubules or F-actin. We propose instead that EB1 reg-
ulates APC to control F-actin levels in cells.
EB1 Levels Govern Directed Cell Migration and F-actin
Levels at Focal Adhesions
Because the directional migration of MDA-MB-231 breast can-
cer cells critically depends on APC-mediated actin nucleation
[15], we wanted to find out whether increasing or decreasing
EB1 levels might alter cell migration. Western blotting verified
EB1 silencing and overexpression in MDA-MB-231 cells (Fig-
ure 4A). Motility assays were performed on cells migrating to-
ward a chemoattractant gradient (0%–10% fetal bovine serum
[FBS]), and the migration paths of more than 971 cells per condi-
tionwere analyzed using FastTrack AI automated analysis (Video
S2; STAR Methods). Rose plots showed that control cells(D) Representative western blots (from two independent blots) showing APC and E
treated (scramble), EB1 knockdown (si-EB1; 96% depletion), APC knockdown (s
91% and 91% respectively), ectopic expression of APC-m4 (78% transfectio
transfection efficiency; si-EB1, 98% depletion). Blots were probed with antibodie
(E) Representative images of F-actin organization (Alexa 568-phalloidin staining)
(F) Quantification of F-actin densities in cells. Box-and-whisker plots represent th
per cell, measured from cell images as in (E). Data are averaged from two indepe
cells). The red dotted line indicates the mean from control cells. Statistical signific
**p < 0.01, n.s., not significant.
See also Figure S2.migrated in a polarized manner toward the gradient, whereas
cells depleted of EB1 or overexpressing EB1 migrated more
randomly (Figure 4B), similar to the reported effects of APC-m4
[15, 16]. Analysis of the migration data showed that altering
EB1 levels (up or down) led to a decrease in cell migration veloc-
ities, directionality indexes, and Euclidean distances (the short-
est distance between start and end points), indicative of random
cell migration (Figures 4C–4E). In addition, EB1 depletion or
overexpression in U2OS cells caused defects in cell migration
in wound healing assays (Figures 4G–4I; Video S3). Analysis of
the trajectories of individual cells migrating at the edge of
wounds showed that EB1 depletion impaired the speed and
directionality of cell movement, whereas EB1 overexpression
led to erraticmotilitywith only slightly reduced velocity (Figure 4I).
Overexpression of EB1Q102E (defective in microtubule binding)
and EB1K89E (defective in microtubule and F-actin binding) led
to similar defects in overexpressed EB1WT (Figures 4F–4I; Video
S3), demonstrating that the effects of EB1 overexpression on cell
migration are independent of its direct binding interactions with
microtubules and F-actin. Together, our observations above
show that perturbation of normal EB1 levels, up or down, dis-
rupts directional cell migration. Importantly, our data do not
rule out the possibility that some of the defects caused by EB1
overexpression are the result of misregulation of its other binding
partners. However, the observation that EB1 overexpression
causes defects similar to APC-m4 is consistent with a model in
which elevated EB1 inhibits APC-mediated actin assembly,
which, in turn, disrupts cell motility. On the other hand, cell
migration defects caused by EB1 knockdown are likely to also
involve loss of EB1 regulatory effects on microtubule dynamics
[25–27].
Finally, we asked whether EB1 regulates actin assembly at
focal adhesions, given that EB1 localizes to these structures
[28–30] and given that focal adhesion turnover depends on
APC-mediated actin nucleation [15, 16, 31, 32]. To assess F-
actin levels at focal adhesions, U2OS cells were co-stained
with Alexa 568-phalloidin and Phospho-Paxillin (P-Pax) (Fig-
ure 4J). Overexpression of EB1WT, EB1Q102E, or EB1K89E signifi-
cantly reduced F-actin levels at focal adhesions, similar to APC-
m4 (Figures 4J and 4K). These results support a role of EB1 in
regulating APC-mediated actin assembly to control focal adhe-
sion turnover and, in turn, directed cell migration.
Conclusions
EB1 was first identified 25 years ago as an in vivo binding part-
ner of APC [1], and subsequent studies demonstrated that
EB1-APC interactions govern microtubule dynamics [6, 7].
However, the potential roles of EB1 in regulating other func-
tions of APC have remained unexplored until now. Our resultsB1 levels in whole-cell extracts fromU2OS cells: untreatedWT (control), mock-
i-APC; 85% depletion), APC and EB1 double knockdown (si-APC and si-EB1;
n efficiency), and APC-m4 combined with EB1 knockdown (APC-m4, 80%
s to APC, EB1, and GADPH (loading control).
in cells as in (D). Scale bar, 25 mm.
e mean and 10–90 percentile values for F-actin density (intensity over cell area)
ndent experiments (left to right/up and down: n = 29, 23, 65, 51, 21, 29, and 46
ance was calculated by one-way ANOVA, Holm-Sidak’s t test: ****p < 0.0001,
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Figure 3. Mutational Dissection of EB1 Effects on Cellular F-actin Levels and Microtubule Organization
(A) Representative western blots (from three independent blots) showing endogenous and overexpressed EB1 levels in U2OS cells: untreated WT (Control),
overexpressing GFP-tagged EB1WT (13.4-fold higher than endogenous EB1), overexpressing GFP-tagged EB1Q102E (12-fold higher), overexpressing GFP-
tagged EB1K89E (18-fold higher), and expressing APC-m4. The OE levels above are the means from three independent experiments. Transfection efficiencies for
all plasmids were 75%–80%.
(B) Representative cell images showing F-actin (Alexa 568-phalloidin staining) andmicrotubules (tubulin immunostaining) for cells as in (A). Cells depleted of APC
(si-APC) were included as an additional control. Scale bar, 25 mm. Boxed regions (yellow) correspond to lower magnified panels (scale bar, 5 mm) and highlight
microtubule staining at the leading edge.
(C)Quantificationof F-actin levels in cells. Box-and-whisker plots represent themean and10–90percentile values for F-actin density (intensity over cell area) per cell
measured from imagesas in (B)and inFigureS3.Dataareaveraged fromtwo independentexperiments (left to right:n=31,21,20,21,20,and20cells). The reddotted
line indicates the mean from control cells. Statistical significance was calculated by one-way ANOVA, Holm-Sidak’s t test: ****p < 0.0001. n.s., not significant.
(D)Quantification ofmicrotubule density at the cell periphery (STARMethods). Box-and-whisker plots represent themeanand 10–90percentile values formicrotubule
densityat the leadingedge fromthesamecells as in (B)and inFigureS3.Dataareaveraged fromtwo independentexperiments (left to right: n=21,21,20,21,20, and20
cells). The reddotted line indicates themean fromcontrol cells.Statistical significancewascalculatedbyone-wayANOVA,Holm-Sidak’s t test: ****p<0.0001, n.s., not
significant.
See also Figure S3.
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Figure 4. Cellular EB1 Levels Govern Directed Migration and F-actin Density at Focal Adhesions
(A) Representative western blot (from two independent blots) showing EB1 and EB1-GFP levels in whole extracts from MDA-MB-231 cells: untreated (Control),
EB1 knockdown (si-EB1; 95% depletion) and overexpressing EB1-GFP (5.8-fold higher than endogenous EB1). Blots were probed with antibodies to EB1 and
GADPH (loading control). The asterisk marks an extra band, likely from degradation of GFP-EB1. The expression levels stated above represent the means from
two independent experiments.
(B) Rose plots showing cell migration angles toward a gradient of FBS in chemotaxis assays, comparing cells as in (A). Data are pooled from three independent
experiments (left to right: n = 1,775, 973, and 1,106 cells).
(legend continued on next page)
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Reportshow that EB1 directly inhibits APC-mediated actin nucleation
in vitro. Further, EB1 depletion leads to increased F-actin levels
in cells, and disrupting APC-mediated actin assembly sup-
presses this effect. Reciprocally, overexpression of EB1 leads
to decreased F-actin levels, consistent with reduced levels of
APC-mediated actin nucleation. These overexpression effects
are independent of EB1 binding to microtubules, and EB1 inhi-
bition of APC is unaffected by mutations in the SxIP motif of
APC-B that mediates EB1-APC microtubule regulatory func-
tions. Thus, EB1 may bind to the basic domain of APC via a
non-canonical interaction to block actin assembly. Given that
EB1 has many in vivo binding partners besides APC, our results
do not exclude the possibility that some of its effects upon
overexpression or depletion are due to misregulation of other
ligands. However, the similarity in phenotypes observed for
EB1 overexpression and APC-m4 expression and the ability
of APC-m4 expression to partially suppress EB1 overexpres-
sion defects suggest that APC-mediated actin assembly is a
key target of control for EB1 in cells.
Because EB1-APC interactions are regulated in vivo by phos-
phorylation [6, 7, 33–36] and control not only actin dynamics
(our data) but also microtubule dynamics [7], we propose that
EB1-APC interactions govern bidirectional microtubule-actin
crosstalk by coordinating microtubule and actin dynamics in
cells. In the future, it will be important to determine how this
is achieved. For instance, when growing microtubule plus
ends (enriched in EB1) reach cortical actin structures (e.g.,
focal adhesions or leading-edge networks), and the microtu-
bules undergo pausing or catastrophe [37–39], they may
release EB1 to inhibit APC-mediated actin assembly. Alterna-
tively, growing microtubule ends may locally recruit (or ‘‘sponge
up’’) EB1, leading to stimulation of APC-mediated actin assem-
bly. It is our hope that the observations reported here, showing
that a direct interaction between these two MAPs (EB1 and
APC) controls actin assembly, inspire future investigations
into the roles of EB1-APC in cytoskeletal crosstalk in other bio-
logical functions and systems.
Finally, does EB1 regulate APC to control cell migration in
intact animals? Although truncations in the C terminus of human
APC lead to colorectal cancer [40–42], mice lacking the C termi-
nus of APC are viable and fertile and exhibit only minor defects in
development [43]. Further, flies lacking the APC gene (APC1) are(C–E) Data from (B) were analyzed using FastTrack AI automated analysis to deter
Shown are the means from three independent experiments. Error bars, SEM. St
***p < 0.001, ****p < 0.0001.
(F) Representative images of wound healing assays at 0 and 8 h fromU2OS cells: u
overexpressing GFP-tagged EB1WT, EB1Q102E, or EB1K89E. Scale bar, 100 mm.
(G) Quantification of wound healing assays as in (F) to compare the speed of wou
bars, SEM. Statistical significance was calculated by one-way ANOVA, Holm-Sid
(H) Initial wound sizes (t = 0 h) were not significantly different under all conditions.
Statistical significance was calculated by one-way ANOVA, Holm-Sidak’s t test:
(I) Representative traces of migration paths for individual cells as in (F) at the wou
displayed in radial arrays where the center (x = 0, y = 0) is the starting point of th
(J) Representative confocal images showing F-actin staining (Alexa-Phalloidin 63
untreated WT (control); overexpressing GFP-tagged EB1WT, EB1Q102E, or EB1K89E
to lower magnified panels (scale bar, 4 mm), highlighting focal adhesions.
(K) Box-and-whisker plots showing F-actin density (fluorescence per unit area) at
and 10–90 percentile values. Data are averaged from two independent experimen
significance was calculated by one-way ANOVA, Holm-Sidak’s t test: ****p < 0.0
See also Videos S2 and S3.
8 Current Biology 30, 1–10, December 7, 2020viable and fertile and show only mild developmental defects [44].
Thus, APC exhibits ‘‘phenotypic robustness,’’ which is also seen
in many other gene knockouts in mammals and flies, including
knockout of the key cytoskeletal regulators CLIP-170 and EB1
[45–49]. This robustness can arise from redundancy with related
or unrelated genes or by compensatory changes in expression of
factors with related functions. In fact, there is a secondAPCgene
(APC2) in mammals and flies with important cytoskeletal func-
tions [50–53] that could be at least partially redundant with
APC/APC1. In addition, there are many other actin nucleation-
promoting factors in cells that could compensate for loss of
APC in animals. Continued genetic analysis in animals will be
required to define the specific pathways and mechanisms that
share roles with APC in vivo.STAR+METHODS
Detailed methods are provided in the online version of this paper
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closure. Data represent the mean from six independent experiments. Error
s t test: **p < 0.01, ***p < 0.001, n.s., not significant.
a represent the mean from six independent experiments. Error bars, SEM.
, not significant.
dge; i.e., moving into the wound (n = 35–38 cells per condition). Paths are
igration path.
nd focal adhesion staining (P-Pax, Phospho-Paxillin Tyr118) in U2OS cells:
d expressing APC-m4. Scale bar, 25 mm. Boxed regions (blue) correspond
idual focal adhesions, measured from images as in (J). Graphs showmean
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ReportSTAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit anti-APC Abcam Cat# ab154906; RRID:AB_2861396
Mouse anti-EB1 BD Bioscience Cat# 610534; RRID:AB_397891
Rabbit/human anti-GADPH Abcam Cat# ab9485; RRID:AB_307275
Rabbit anti-phospho-Paxillin (Tyr 118) ECM Biosciences Cat# PP4501; RRID:AB_2861397
Mouse BM75.2 alpha-actinin Sigma-Aldrich Cat# A5044; RRID:AB_476737
Mouse alpha-tubulin antibody Santa Cruz Biotechnology Cat# sc-32292; RRID:AB_2110259
Goat anti-mouse AlexaFluor-488 Thermo Fisher Scientific Cat# A32723; RRID:AB_2633275
Goat anti-rabbit AlexaFluor-555 Thermo Fisher Scientific Cat# A-21428; RRID:AB_2535849
Goat anti-mouse AlexaFluor-633 Thermo Fisher Scientific Cat# A-21050; RRID:AB_2535718
Donkey anti-rabbit IRDye 680RD LI-COR Biosciences Cat# 926-68073; RRID:AB_10954442
Goat anti-mouse IRDye 680RD LI-COR Biosciences Cat# 926-68070; RRID:AB_10956588
Donkey anti-rabbit IRDye 800RD LI-COR Biosciences Cat# 926-32213; RRID:AB_621848
Bacterial and Virus Strains
XL Blue competent cells Agilent Cat# 200249
Chemicals, Peptides, and Recombinant Proteins
Alexa Fluor 594 C5 Maleimide Thermo Fisher Scientific Cat# A10256
Turbo Labeling Kit, Cy5 dye Thermo Fisher Scientific Cat# KIT0610
EB1 [21] Bruce Goode-US
594-EB1 This paper Bruce Goode-US
APC-B [19] Bruce Goode-US
SNAP-APC-B This paper Bruce Goode-US
APC-C [19] Bruce Goode-US
SNAP-APC-C [19] Bruce Goode-US
APC-B-LRDP This paper Bruce Goode-US
SNAP-APC-B-LRDP This paper Bruce Goode-US
Daam1 [19] Bruce Goode-US
Profilin [19] Bruce Goode-US
CapZ [19] Bruce Goode-US
AlexaFluor-568-Phalloidin Invitrogen-Thermo Fisher Scientific Cat# A12380
AlexaFluor-633-Phalloidin Invitrogen-Thermo Fisher Scientific Cat# A22284
200 mM L-glutamine Thermo Fisher Scientific Cat# 25030-081
DMEM- Dulbecco’s Modified Eagle
Medium
Thermo Fisher Scientific Cat# 11995-073
UltraCulture serum-free medium Lonza Cat# 12-725F
FBS – Fetal bovine serum Sigma-Aldrich Cat# F9423
Lipofectamine 3000 Thermo Fisher Scientific Cat# L3000-015
Lipofectamine RNAiMAX Thermo Fisher Scientific Cat# 13778075
Opti-MEM reduced serum media Thermo Fisher Scientific Cat# 11058021
Collagen I Corning Cat# 354236
Glutaraldehyde, EM Grade 25% Polysciences Cat# 01909-10
Formaldehyde 16% - methanol free Thermo Scientific Cat# 28908
(Continued on next page)Current Biology 30, 1–10.e1–e8, December 7, 2020 e1
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Experimental Models: Cell Lines
Human osteosarcoma cells: U2OS ATCC Cat# HTB-96; RRID:CVCL_0042
Human breast cancer cells: MDA-MB-231 ATCC Cat# HTB-26; RRID:CVCL_0062
Oligonucleotides
siRNA targeting sequence against the
human EB1: 50- UUAAAUACUCUUA
AGGCAUUU-30 sense and 50-
AAAUGCCUUAAG
AGUAUUUAA-30 antisense
Integrated DNA Technologies Custom oligos
siRNA targeting sequence against the
human APC: 50-GGAUCUGUAUC
AAGCCGUUTT-30 sense and 50-
AACGGCUUGA
UACAGAUCCTT-30 antisense
Thermofisher Scientific Cat# 4390824





Plasmid: APC-m4 [19] Bruce Goode-US
Plasmid: EB1-GFP Addgene RRID:Addgene_39299
Plasmid: EB1-Q102E-GFP This paper Bruce Goode-US
Plasmid: EB1-K89E-GFP This paper Bruce Goode-US
Software and Algorithms
NIS Elements software - version 4.20 Nikon Instruments https://www.nikoninstruments.com/
Products/Software, RRID:SCR_014329
FastTrack AI automated analysis system -
Chemotaxis
MetaVi Labs / Ibidi https://www.metavilabs.com/sites/default/
files/help_center/chemotaxis.html,
Cat#32200-3
Wound Healing Automated Cellular
Analysis System analysis
MetaVi Labs /Ibidi https://www.metavilabs.com/sites/default/
files/help_center/wound_healing.html,
Cat# 32000-250





GraphPad Prism 6.0c GraphPad Software RRID: SCR_002798
Adobe Illustrator CS6 Adobe Illustrator (Adobe Systems) http://www.adobe.com/products/
illustrator.html, RRID:SCR_010279
Imaging Lab version 6.0.0 software Image Lab Software (Biorad) http://www.bio-rad.com/en-us/sku/
1709690-image-
lab-software, RRID:SCR_014210
MATLAB R2019a MATLAB http://www.mathworks.com/products/
matlab/, RRID:SCR_001622
Fiji / ImageJ NIH – public domain http://fiji.sc, RRID:SCR_002285
Other
AquaMount mounting media Thermo Fisher Scientific Cat# 14-390-5
Circular Round cover glasses 0.15 mm Thermo Fischer Scientific Cat# 12-545-80
mSlide chemotaxis collagen IV Ibidi Cat# 80322
Culture-Inserts 2 well Ibidi Cat# 81176
Ni-NTA-agarose beads QIAGEN Cat# 30230
GSTrap column GE Healthcare Cat# 45000281
Centricon spin concentrators Milipore Cat# UFC800324
G-25 desalting columns (PD-10) GE Healthcare Cat# 17085101
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Requests for further information and reagents should be directed to and will be fulfilled by the Lead Contact, Bruce Goode (goode@
brandeis.edu).
Materials Availability
This study generated new plasmids for purifying proteins, which will be made available upon request to the Lead Contact Bruce
Goode.
Data and Code Availability
The processed image data and the original MATLAB code for this article have been deposited to Zenodo: https://zenodo.org/record/
4019683#.X2ktiC2ZOgQ: In addition, all of the raw (original and unprocessed) data have been uploaded to a Google Drive and will be
made available upon request to the lead contact (Bruce Goode).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Purified proteins are as described in Method Details. Human osteosarcoma (U2OS, HTB96) and human breast cancer (MDA-MB-
231, HTB-26) cell lines were obtained directly from ATCC (American Type Culture Collection; Manassas, VA, USA), where their iden-
tities were authenticated by short tandem repeat DNA profiling and they were tested for mycoplasma contamination. Cell lines were
used for amaximumof 25 passages. All cells were grown in DMEM (GIBCO, Life technologies, Grand Island, NY, USA) supplemented
with 200mM L-glutamine (Thermo Fisher Scientific, Waltham, MA), 10% fetal bovine serum (FBS; Sigma-Aldrich, St. Louis, MO), and
50 units/ml Penicillin and 50 mg/ml streptomycin (GIBCO, Thermofisher), at 37C and 5% CO2.
METHOD DETAILS
Plasmid construction
A plasmid (pBG2404) for E. coli expression and purification of SNAP-APC-Bwas constructed by isolating the coding sequence of the
APC-Basic domain (residues 2167-2674) from pBG721 (pGEX-6p harboring APC-B) [17] using EcoRI and NotI, and subcloning this
DNA fragment into the same sites in pGEX-6p. Site-directed mutagenesis was used to introduce the two point mutations in APC-
BLRDP into the same plasmid with these oligos: forward 50-TCT GAA AGT CCT CTG AGA GAT CCA ATC AAT AGG-30 and reverse
50- CCT ATT GAT TGG ATC TCT CAG AGG ACT TTC AGA-30 (underlined nucleotides deviate from the wild-type sequence). Site-
directed mutagenesis also was used to generate EB1 mutants Q102E and K89E, with the following oligos: Q102E, forward
50-GGA AAG TTT GAG GAC AAT TTT GAA TTC GTT CAG-30 and reverse 50-CTG AAC GAA TTC AAA ATT GTC CTC AAA CTT
TCC-30; K89E, forward 50-ATG GGT GTT GAC GAA ATA ATT CCT GTG GAC-30 and reverse 50-GTC CAC AGG AAT TAT TTC
GTC AAC ACC CAT-30 (underlined nucleotides deviate from wild-type sequence).
Protein purification
Rabbit muscle actin (RMA) was purified from acetone powder and Cys-374-labeled with Oregon Green (OG) as described [54, 55].
Actin was partially extracted from skeletal muscle tissue and stored as ‘acetone powder’ at80C. Acetone powder was pulverized
using a coffee grinder and liquid N2, resuspended in G-buffer, and cleared by centrifugation at 50,000 x g. The actin was polymerized
overnight at 4C by addition of 50 mM NaCl and 2 mM MgCl2. Then 0.6 M NaCl was added to F-actin to dissociate actin binding
proteins, and the F-actin was pelleted by centrifugation at 361,000 x g for 2.5 hr. F-actin pellets were resuspended in G-buffer,
dounce-homogenized, and dialyzed three times against G-buffer for 2-3 days. For use in bulk actin assembly assays, RMA was fluo-
rescently labeled with N-(1-pyrenyl) iodoacetamide on cysteine 374 [56]. RMA prepared as above excluding the gel-filtration step
was dialyzed against pyrene buffer (25 mM Tris-HCl pH 7.5, 100 mM KCl, 0.02% NaN3, 0.3 mM ATP, and 2 mM MgSO4) for 3-
4 hr, and then diluted with pyrene buffer to 1 mg/mL (23.8 mM). A 7-fold molar excess of pyrenyl-iodoacetamide was added, and
the actin solution was incubated overnight at 4C, then aggregates were cleared by low-speed centrifugation. The supernatant (con-
taining F-actin) was centrifuged for 3 hr at 4C at 264,000 x g in a Ti70 rotor (Beckman Coulter Inc.; Brea, CA) to pellet F-actin. F-actin
pellets were homogenized by douncing, dialyzed against G-buffer for 1-2 days, and gel-filtered on a 16/60 S200 column as above.
Peak fractions were pooled, aliquoted, snap-frozen, and stored at 80C until use.
For TIRF microscopy assays, actin was polymerized and labeled overnight at 4C using a 12 molar excess of oregon green (OG)-
iodoacetamide (Thermo Fisher Scientific, Waltham, MA) in labeling buffer (25 mM imidazole pH 7.5, 100 mM KCl, 0.15 mM NaATP,
and 2 mM MgCl2). Actin was polymerized and labeled overnight at 4C by addition of a 12 molar excess of OG-iodoacetamide
(Thermo Fisher Scientific, Waltham, MA) in labeling buffer (25 mM imidazole pH 7.5, 100 mM KCl, 0.15 mM NaATP, and 2 mM
MgCl2). Labeled actin was pelleted at 100,000 x g for 3 hr at 4C, resuspended, and dounced in G-buffer, then dialyzed against
G-buffer as above. Labeled G-actin was clarified at 264,000 x g for 30 min, and gel filtered using a HiPrep S200 (16/60) column equil-
ibrated in G-buffer. Peak fractions containing OG-RMAwere dialyzed against G-buffer with 50%glycerol and stored at20C (where
it remains stable for months). Every 1-2 weeks, an aliquot of OG-RMA stored at 20C was dialyzed against fresh G-buffer andCurrent Biology 30, 1–10.e1–e8, December 7, 2020 e3
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Reportclarified by centrifugation at 353,000 x g for 30 min. Actin concentration was determined by absorbance using a Ɛ290 of 26,600
M-1cm-1. Labeling percentage was calculated using the dye Ɛ493 of 77,800 M-1cm-1 with a correction factor (cf.) of 0.16991
(Equation 1).
½Actin = A290  ðA493  cfÞ
ε290
Equation 1
6His-C-Daam1 (FH1-FH2-C) was expressed in S. cerevisiae strain BJ2168 from a high copy (2 micron) plasmid under control of a
galactose-inducible promoter [57]. For each preparation, 2L of yeast cells were grown in synthetic medium lacking uracil and 2%
raffinose to OD600 = 0.8, then expression was induced by addition of galactose (2% final), and cells were grown for another 8-
12 hr at 30C. Cells were washed in H2O, frozen in liquid N2, and lysed by mechanical disruption using a coffee grinder and liquid
N2. The resulting frozen yeast powder was stored at 80C until use. C-Daam1 was then purified as described [57, 58]. Briefly,
10 g of frozen yeast powder was resuspended in buffer A [30 mM Imidazole pH 8.0, 0.5 mM DTT, 2XPBS (40 mM sodium phosphate
buffer, 200 mM NaCl, pH 7.4)] with 150mM NaCl, 1% NP-40, standard protease inhibitors and 2 mM phenylmethylsulfonyl fluoride
(PMSF) until all of the clumps were dissolved, and then cleared by ultracentrifugation at 300,000 x g for 20 min at 4C in a TLA100.3
rotor (Beckman Coulter Inc.). The supernatant was incubated with 500 mL Ni-NTA-agarose beads (QIAGEN, Valencia, CA) for 2 hr at
4C, and then beads were washed three times with buffer A containing 350mMNaCl, followed by three washes with buffer A. Protein
was eluted from the beads with buffer A supplemented with 350 mM imidazole (pH 8.0) and 0.5 mM DTT, and purified further on a
Superose 6 gel filtration column (GE Healthcare) equilibrated in buffer HEKG5D [20 mMHEPES pH 7.5, 1 mM EDTA, 50 mM KCl, 5%
(v/v) glycerol, 1 mM DTT]. Peak fractions were pooled, concentrated, aliquoted, snap frozen, and stored at 80C.
Human profilin was purified as described [59]. Briefly, a plasmid expressing human profilin [59] was transformed into BL21(DE3)
E. coli cells, which were then grown to OD600 = 0.5 in Terrific Broth plus antibiotics. Protein expression was induced for 3 hr at 37C
with 0.4 mM IPTG. Cells were harvested by centrifugation and stored at80C. Cell pellets were resuspended in lysis buffer (50 mM
Tris pH 8.0, DNase, lysozyme and complete protease inhibitors), kept on ice for 20 min, then lysed by sonication (four pulses of 30 s).
Lysates were cleared for 30 min at 14,000 rpm, and the supernatant was loaded on a QFF column (GE Healthcare) equilibrated in
20mM Tris pH 8.0 and 50 mM NaCl, and eluted with a salt gradient (0-1 M NaCl). Peak fractions were pooled, concentrated and pu-
rified further on a Superdex 75 column (GE Healthcare) equilibrated with in 20 mM Tris pH 8.0 and 50 mM NaCl. Peak fractions were
pooled, concentrated, aliquoted, snap frozen, and stored at 80C.
Human CapZ was purified as described [60]. Briefly, a plasmid expressing human CapZ [61] was transformed into BL21(DE3)
pLysS E. coli cells, and cells were grown to OD600 = 0.8 in LB plus antibiotics. Protein expression was induced for 3 hr at 37C
with 0.4 mM IPTG. Cells were harvested by centrifugation and stored at 80C. Cell pellets were resuspended in lysis buffer
(20 mM Tris-Cl pH 8.0, 1mM EDTA, 0.2% Triton X-100, lysozyme and complete protease inhibitors), kept on ice for 30 min, and
then lysed by sonication (four pulses of 30 s). Lysates were cleared for 30 min at 14,000 rpm at 4C, and the supernatant was
collected and loaded on a QFF column (GE Healthcare) equilibrated in 20 mM Tris pH 8.0 and 50 mM NaCl and eluted with a salt
gradient (0-1 M NaCl, 20 mM Tris pH 8.0). Peak fractions were pooled, concentrated and further fractionated on a Superdex 75 col-
umn (GEHealthcare) equilibratedwith in 20mMTris pH 8.0 and 50mMNaCl. Peak fractionswere pooled, loaded on amonoQ column
equilibrated in 20 mM HEPES pH 6.8 and 1 mM EDTA, and eluted with a salt gradient (0-500 mM KCl). Peak fractions were pooled,
dialyzed overnight into HEK buffer (20mMHEPES pH 7.5, 1mMEDTA, and 50mMKCl), snap frozen in aliquots, and stored at80C.
APC-B, APC-C, SNAP-APC-B, and SNAP-APC-C proteins were purified essentially as described [15] with minor modifications, as
follows. Briefly, plasmids expressing APC constructs were transformed into E. coli BL21(DE3) pLysS cells, and cells were grown to
OD600 = 0.8 in Terrific Broth plus antibiotics. Protein expression was induced for 4 hr at 37Cwith 0.4mM IPTG. Cells were harvested
by centrifugation, flash frozen and stored at 80C. Cell pellets were resuspended in cold lysis buffer (30 mM Tris pH 8.0, 600 mM
KCl, 1 mM EDTA pH 8.0, 1 mM DTT, DNase, lysozyme, complete protease inhibitor cocktail and 0.2 mM PMSF), homogenized by
douncing, and lysed by sonication (4 pulses of 30 s). Lysates were cleared for 30 min at 33,5003 g, and the supernatant was mixed
with 0.5 mL glutathione-agarose beads (Thermo Fisher Scientific, Pittsburgh, PA), and incubated for 1 hr at 4C. Beads were washed
three times in 30 mM Tris pH 8.0, 600 mMKCl, 1 mM EDTA pH 8.0, and proteins were eluted in the same buffer plus 5% glycerol and
30 mM glutathione. Eluted proteins were mixed with 0.5 mL Ni-NTA-agarose beads in 30 mM Tris pH 8.0, 600 mM KCl, 1% Triton X-
100, plus 30mM Imidazole, and incubated for 1 hr at 4C. Beads were then washed three times in the same buffer lacking detergent,
and fractions were eluted in the same buffer plus 300 mM Imidazole. Peak fractions were pooled, dialyzed overnight into HEKG5
buffer (20 mM HEPES, pH 7.5, 1mM EDTA, 150 mM KCl, and 5% glycerol), aliquoted, snap-frozen, and stored at 80C. SNAP-
tagged APC-B protein was purified in the same manner, except while still on the Ni-NTA-agarose beads it was labeled overnight
at 4C with 50 mM SNAP-Surface649 dye (NEB, Ipswich, MA). Beads were washed five times to remove excess dye, and proteins
were eluted, dialyzed, aliquoted, and stored as above. Percent labeling of SNAP-APC-B and SNAP-APC-C was determined by
measuring fluorophore absorbance using the extinction coefficient for SNAP-surface 649: ε655 = 250,000 M-1 cm-1. SNAP-APC-
B and SNAP-APC-C labeling efficiency was 80%–86% for different batches. Concentrations of proteins were determined by
band intensity on Coomassie-stained gels compared to a BSA standard curve using a BioRad Chemidoc MP imaging system,
and quantified by densitometry using Imaging Lab version 6.0.0 software (Biorad).
Wild-type and mutant EB1 proteins were purified essentially as described [17], with minor modifications as follows. Briefly, plas-
mids expressing GST-EB1 proteins were transformed into fresh competent E. coli cells and grown in Terrific Broth under antibiotic
selection. Induction tests showed that inducing expression with IPTG yielded insoluble proteins, and therefore, GST-EB1 wase4 Current Biology 30, 1–10.e1–e8, December 7, 2020
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Reportpurified from cells without inducing expression, which yielded soluble proteins. Cells were harvested by centrifugation and stored at
80C. Cell pellets were resuspended in cold lysis buffer (30 mM Tris pH 8.0, 150 mM KCl, 1 mM EDTA pH 8.0, 1 mM DTT, DNaseI,
lysozyme, complete protease inhibitor cocktail and 0.2mMPMSF), and lysedwith lysozyme for 30min, mixing occasionally by gentle
inversion. Lysates were cleared for 15min at 10,0003 g, and then cleared using a syringe filter (0.22 mm). Clarified lysates were slowly
loaded on a GSTrap column (GE Healthcare) equilibrated in lysis buffer. After washing, Precision protease was added to the GSTrap
column, and incubated overnight at 4oC to release untagged EB1. Released protein was eluted in lysis buffer, concentrated, and
exchanged into HEKG10 buffer (20 mM HEPES, pH 7.5, 1mM EDTA, 150 mM KCl, and 10% glycerol) using a G-25 desalting column
(GE Healthcare), then aliquoted, snap-frozen, and stored at 80C. In some cases, purified EB1 was labeled on surface cysteines
using Alexa Fluor 594 C5 Maleimide (Thermo Fisher Scientific). This was achieved by exchanging EB1 into HEKG10 with 10 mM
TCEP and a 5 molar excess of dye, and incubating overnight at 4C. Free dye was removed using a gravity G-25 desalting columns,
and the protein was aliquoted, snap-frozen, and stored at80C. Percent labeling was determined bymeasuring fluorophore absor-
bance using the extinction coefficient for Alexa Fluor 594 C5 Maleimide: ε655 = 250,000 M-1 cm-1. EB1-594 labeling efficiency was
20%–26% for different batches.
Bulk assays
For pyrene-actin assembly assays, gel filteredmonomeric actin (2 mM; 5%pyrene-labeled) in G-buffer (5mMTris-HCl pH 8.0, 0.2mM
ATP, 0.2mMCaCl2, and 0.2mMDTT) was converted toMg-ATP-actin immediately before each reaction as described [62]. Actin was
mixed with proteins or control buffer, then 3 mL of 20 3 initiation mix (40 mM MgCl2, 10 mM ATP, 1 M KCl) was added to initiate
polymerization. Fluorescence was monitored at excitation 365 nm and emission 407 nm at 25C in a fluorimeter (Photon Technology
International, Lawrenceville, NJ). For measuring G-actin binding by change in fluorescence, 100 nMCa-ATP–G-actin (100% pyrene-
labeled) was incubated for 60min with 100 nM Latrunculin B in G-buffer. Then, 55 mL of this mixture was added to 5 mL APC-B and/or
EB1 at different concentrations (0–1000 nM) in HEKG5 buffer, incubated for 60 min at room temperature to reach steady state, and
then pyrene fluorescence was measured in a fluorimeter at 25C using excitation 365 nm and emission 407 nm.
In vitro TIRF microscopy and single molecule binding assays
Glass coverslips (60 3 24 mm; Thermo Fisher Scientific) were cleaned by sonication for 30 min in detergent, followed by 1 M KOH,
and 1 M HCl, and then stored in 100% ethanol. To biotin-anchor SNAP-APC proteins to the surface for single molecule binding as-
says, coverslips were first coated with a mixture of 4 mg/mL polyethylene glycol (PEG)-silane and 80 mg/mL biotin-PEG in 80%
ethanol pH 1.0, then washed with water and dried with compressed N2. PEG-coated coverslips were stored for 1-3 days at 70C
prior to use. Flow chambers were constructed by sandwiching coverslips on top of plastic flow chambers (Ibidi, Fitchburg, WI) using
double-sided tape (2.5 cm 3 2 mm 3 120 mm) and five-minute epoxy resin (Devcon, Riviera Beach, FL).
For each TIRF reaction, 4 mg/mL streptavidin in HEK buffer (20 mM HEPES pH 7.4, 1 mM EDTA, 50 mM KCl) was flowed into the
chamber for 15 s using a syringe pump (Harvard Apparatus, Holliston, MA), followed by washing with HEK buffer + 1% BSA. The
chamber was then equilibrated with TIRF buffer (10 mM HEPES pH 7.4, 50 mM KCl, 1 mM MgCl2, 1 mM EGTA, 0.2 mM ATP,
10 mM DTT, 15 mM glucose, 20 mg/mL catalase, 100 mg/mL glucose oxidase, 10 mM Imidazole, and 0.5% methylcellulose (4000
cP)). Where indicated, APC-B and EB1 proteins were diluted into TIRF buffer, and rapidly mixed with 1 mM actin monomers (10%
OG-labeled, 0.2% biotinylated) and introduced into the flow. The flow cell was then immediately mounted on the microscope stage
for imaging. The delay between mixing of proteins and initial imaging was 30 s. Time-lapse TIRF imaging was performed on a Ti200
invertedmicroscope (Nikon Instruments, NewYork, NY) equippedwith 100mWsolid-state lasers (Agilent Technologies, Santa Clara,
CA), a CFI Apo 603 1.49 N.A. oil-immersion TIRF objective (Nikon Instruments), a iXon EMCCD camera with a pixel size of 0.267 mm
(Andor Technology), and an additional 1.53 zoommodule (Nikon Instruments). Focus was maintained using the Perfect Focus Sys-
tem (Nikon Instruments), and frames were captured every 5 s for a total of 600 s (10 ms at 488nm excitation, 10% laser power) using
NIS Elements software (Nikon). Image analysis was performed in ImageJ. Background fluorescence was removed from each time
series using the background subtraction tool in Fiji (rolling ball radius, 50 pixels). For measuring the number of actin filaments nucle-
ated in TIRF reactions, fields of view were analyzed 300 s after the initiation of actin assembly.
For single molecule colocalization experiments, 25 pM SNAP-649-Biotin-APC-B (89% labeled), SNAP-649-Biotin-APC-C (60%
labeled), or SNAP-649-Biotin-APC-BLRDPmolecules (84% labeled) was preincubated for 1 hr with 500 nM EB1-Alexa-594 (24%
labeled) in TIRF buffer, then introduced into the flow chamber and imaged. Labeled APC proteins were anchored to the viewing sur-
face, and then APC and bound EB1molecules were imaged in separate channels. Images were collected at 100ms exposures times
for each channel and 10-20 images were collected per condition. Images analysis was performed using a custom written MATLAB
(Natick, MA) code. Background fluorescence was subtracted from each image using a rolling average, and manual thresholding was
used to generate a binary mask of each channel. Colocalization was defined as overlap of at least 3 pixels from each protein spot in
each of the binary masks. The fraction of APC molecules with EB1 bound (colocalized spots) was determined. Only 20% of the
anchored labeled APCmolecules were competent to bind EB1 (Figures 1G and 1H). This is a common observation in single molecule
binding assays, as tethering to the surface can render a large fraction of anchoredmolecules incapable of binding to a specific ligand
[63]. Fortunately, the ‘inactive’ fraction of APC molecules, which do not bind EB1, do not impact the binding behavior of the remain-
ing, active APCmolecules with EB1, and thus do not impact the analysis or the interpretation of the results. The specificity of binding
between EB1 and APC (C-terminal third of protein) has been demonstrated in previous studies [1, 6]. As an additional control for non-
specific interactions, we verified that EB1 binding to anchored APC molecules on the surface was reversible, i.e., EB1 moleculesCurrent Biology 30, 1–10.e1–e8, December 7, 2020 e5
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Reporteventually dissociated from APC, and that this effect was not due to photobleaching. Additionally, we observed no colocalization
between labeled EB1 and APC after the images of the two channels (EB1 and APC) were rotated by 90 degrees with respect to
each other. Thus, colocalization does not arise from non-specific interactions of EB1 with the surface.
RNAi silencing and plasmid transfections
As mentioned above, human osteosarcoma (U2OS, HTB96) and human breast cancer (MDA-MB-231, HTB-26) cell lines were ob-
tained from ATCC. Cell culture experiments, for both cell lines, were carried out in 6-well plates (MatTek Corporation, Ashland,
MA), seeding each well with approximately 60,000 cells. Transfection efficiencies (for both U2OS and MDA-MB-231 cells) were opti-
mized by carefully titrating the loads of oligos and plasmids, and testing different incubation times for key steps in the transfection
protocol. This resulted in consistent transfection efficiencies of 75%–80% for plasmids, quantified by visualization of the plasmid-
derived GFP signal, and 85%–99% for APC and EB1 knockdowns, quantified by visualizing uptake of a Cy5-labeled dye mixed
with the knockdown oligos. To silence endogenous EB1, 8-12 hr after seeding, cells were transfected with 60 nM RNAi oligos using
Lipofectamine RNAiMAX (Thermo Fisher Scientific), according to the manufacturer’s instructions. RNAi oligos were directed against
the 30 UTR region of human EB1 (si-EB1): 50-UUAAAUACUCUUAAGGCAUUU-30 sense and 50-AAAUGCCUUAAGAGUAUUUAA-30
antisense [26] (Integrated DNA Technologies, Inc., Coralville, Iowa, USA). To silence endogenous APC, 8-12 hr after seeding, cells
were transfected with 50 nM RNAi oligos using Lipofectamine 3000 (Thermo Fisher Scientific), according to the manufacturer’s in-
structions. RNAi oligos were directed against the mRNA coding region of human APC (si-APC): 50-GGAUCUGUAUCAAGCCGUUTT-
30 sense and 50-AACGGCUUGAUACAGAUCCTT-30 antisense [15] (Thermo Fisher Scientific). Cells were transfected in parallel with
control ‘scramble’ RNAi oligos: 50-CAGUCGCGUUUGCGACUGG-30 with dTdT 30 overhangs. For EB1 rescue experiments, 10-12 hr
after silencing, cells were transfected with 200 ng of human EB1-GFP plasmid as in Juanes et al. [15], using Lipofectamine 3000. For
EB1-GFP wild-type (EB1WT) andmutants (OE-EB1Q102E or OE-EB1K89E), and APC-m4 experiments, 10-12 hr after seeding cells, 1 mg
of plasmid was introduced ectopically in cells, without depletion of endogenous EB1 or APC using Lipofectamine 3000 (Thermo
Fisher Scientific). 24 hr after EB1 or APC plasmid transfection, the cells were collected for western blotting or replated for 6-8 hr prior
to fixation and immunofluorescence.
Western blotting
Western blotting was used to determine endogenous EB1 and APC proteins levels after RNAi silencing, and ectopic EB1 and APC
levels after rescue or overexpression of EB1 and ectopic expression of APC-m4 in U2OS andMDA-MB-231 cells. Cells were pelleted
and resuspended in lysis buffer (150 mMNaCl, 1.0%NP-40, 1.0% sodium deoxycholate, 1% SDS, 50 mM Tris, pH 7.5, 2 mM EDTA,
0.2 mM sodium orthovanadate, 20 mM b-glycerophosphate, 50 mM sodium fluoride, 1 mM PMSF, 1 mM DTT, and 13 Roche com-
plete protease inhibitor mixture), and incubated at 4C for 30 min with vortexing every 2 min. Lysates were precleared by centrifu-
gation at 15,300 x g for 20 min at 4C, and the soluble protein concentration was determined by Bradford assay (Biorad, Hercules,
CA). Equal amounts of lysate (total protein) were compared on immunoblots. Blots were probed with 1:1000 mouse anti-EB1 (Clone
5/EB1 #610534; BD Transduction Laboratories), 1:500 rabbit anti-APC (ab154906; Abcam, Cambridge MA), 1:2000 rabbit anti-GFP
(ab6556; Abcam), or 1:2000 rabbit/human anti-GADPH (ab9489; Abcam, Cambridge, MA). Blots were washed and probed with
infrared dye–conjugated secondary antibodies (Rockland Immunochemicals, Pottstown, PA). Bands were detected using a BioRad
Chemidoc MP imaging system, and quantified by densitometry using Imaging Lab version 6.0.0 software (Biorad). GADPHwas used
as loading control. For the quantitative western blots used to determine levels of endogenous EB1 and APC, known amounts of pu-
rified EB1 or APC-C (residues 2130-2843) were run on gels alongside U2OS cell lysates, blotted, and probed with anti-EB1 or anti-
APC antibodies. Band densitometry as above was used to generate a standard curve for the purified proteins, and the amount of EB1
or APC protein in the cell lysates was determined by comparison to the standard curves. Values were averaged from three indepen-
dent blots. For calculations of cellular concentrations of EB1 and APC, the concentration of total protein in the cytoplasm was
assumed to be 100 mg/ml [36]. The amount (in grams) of EB1 and APC in 25 or 60 mg of lysate, respectively, was determined,
and then the molar concentration of each protein was calculated based its known molecular weight and the considerations above.
Immunostaining of fixed cells
Transfected cells were replated for 16-18 hr on 33 13 1mmglass coverslips (VWR International, Radnor, PA), which had been acid-
washed and precoated with collagen I (Advanced BioMatrix, Carlsbad, CA). For imaging endogenously-expressed phospho-Paxillin
(P-Pax) and/or overexpressed EB1-GFP (to validate transfection) along with F-actin, cells were fixed at room temperature for 15 min
using 4% Formaldehyde methanol-free in 1 3 PBS (2.7 mM KCl, 1.8 mM KH2PO4, 10 mM Na2HPO4, 140 mM NaCl pH 7.4), per-
meabilized for 10 min in 13 PBS plus 0.5% Triton X-100 and 0.3 M glycine, and incubated for 1 hr at room temperature in a solution
of 1% BSA dissolved in PBST (13 PBS, 0.1% v/v Tween-20). For immunostaining, cells were incubated for 12 hr at 4Cwith primary
antibody 1:500 rabbit anti-phospho-Paxillin (Tyr118) (PP4501; ECMBiosciences). Next, coverslips were washed three times with 13
PBST and incubated for 1 hr at room temperature with secondary antibody 1:1000 goat anti-rabbit Alexa Fluor-555 (A-21428, Thermo
Fisher Scientific) along with 1:1000 Phalloidin-568 (A-12380, Thermo Fisher Scientific) to stain F-actin. Then coverslips were washed
three times with 13 PBS plus 0.1% Tween-20, once with PBS, and mounted with AquaMount (Thermo Fisher Scientific) before im-
aging. Cells were imaged on a Nikon i-E upright confocal microscope (Nikon Instruments) equipped with a CSU-W1 spinning disk
head (Yokogawa, Tokyo, Japan), 100 mW solid-state lasers, an emission tuner for 561 nm wavelength, 60x oil objective (NA 1.4; Ni-
kon Instruments), and an Ixon 897 Ultra-CCD camera (Andor Technology). Images were captured as stacks (9 planes, 0.5 mm steps,e6 Current Biology 30, 1–10.e1–e8, December 7, 2020
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Report60%–80% laser power) with sequential 100-200 ms exposures at 561 nm using Nikon Elements software (version 4.30.02; Nikon
Instruments).
For imaging endogenous alpha-actinin and alpha-tubulin, alongside F-actin, cells were fixed and permeabilized as above, and then
incubated for 1 hr at room temperature with 1:100 mouse BM-75.2 alpha-actinin antibody (A5044, Sigma-Aldrich), or with 1:1000
mouse alpha-tubulin antibody (sc-32292; Santa Cruz Biotechnology). After washes with 1 3 PBST, coverslips were incubated for
1 hr at room temperature with 1:1000 Phalloidin-568 (A-12380, Thermo Fisher Scientific) to stain F-actin, and either 1:1000 goat
anti-mouse AlexaFluor-488 (A-32723) for alpha-actinin or 1:1000 goat anti-mouse AlexaFluor-633 (A-21050) for alpha-tubulin. Cells
were imaged on a laser scanning confocal inverted Nikon Ti-E-PFS3 eclipse microscope (Nikon Instruments, New York, NY) equip-
ped with 100mW solid-state laser and emission tuner for 488, 561, 633 nmwavelengths, a 60x (NA 1.4) oil-immersion objective, a C2
imaging head (Nikon Instruments), and a 7-LED Light Engine array and a sCMOS camera (Andor Zyla) at room temperature. Images
were acquired using Nikon Elements software (version 4.30.02) with 23 averaging stacks (7 planes stacks, 0.5 mmsteps) at 1% laser
power, with 32 ms exposures for alpha-actinin and F-actin; and 17 ms exposures for tubulin and F-actin.
To control for the loss of labile actin structures in our cell staining, we performed separate experiments (Figures S2B andS2C) using
a different fixation method optimized for preserving the actin cytoskeleton [22]. Cells were fixed on coverslips with pre-warmed 4%
formaldehyde methanol-free in 13 PBS (2.7 mM KCl, 1.8 mM KH2PO4, 10 mM Na2HPO4, 140 mM NaCl pH 7.4) and 0.25% glutar-
aldehyde for 20min. This combination of fixatives increases the degree of crosslinking. Coverslips were thenwashed three timeswith
warm 13 PBS, permeabilized for 1 min using 13 PBS plus 0.1% Triton X-100, washed three times with room temperature 13 PBS,
incubated for 1 hr at room temperature with 1:200 Phalloidin-568 (A-12380, Thermo Fisher Scientific), and finally washed three times
with room temperature 1 3 PBS. Cells were imaged as above on the laser scanning confocal inverted Nikon Ti-E-PFS3 eclipse mi-
croscope (Nikon Instruments, New York, NY) except using a 100x (NA 1.45) oil-immersion objective. Images were acquired using
Nikon Elements software (version 4.30.02) with 2 3 averaging stacks (7 planes stacks, 0.5 mm steps) at 1% laser power with a
32 ms exposure.
Fiji was used to generate maximum intensity projections from all images. For each cell, the raw cellular fluorescence intensity and
cell area, calculated using Fiji, was used to determine F-actin and alpha-actinin densities (fluorescence intensity divided by cell area).
To quantify microtubule density at the leading edge, a box (153 15 mm2) was positioned at the cell edge, extending back toward the
center of the cell, andmean fluorescence intensity wasmeasured in the box using Fiji and shown per mm2. To quantify F-actin density
at individual focal adhesions, the ratio of the integrated fluorescence intensity of F-actin versus Phospho-Paxillin (P-Pax) at each focal
adhesion was quantified in an automated fashion using a custom script in MATLAB.
Wound healing and chemotaxis assays
For would healing assays, U2OS cells (1 3 106) were plated on 6-well dishes, then cells were transfected with siRNA oligos and/or
plasmids as described. After 24 hr, cells were replated onto m-dishes 35 mm containing a sterile silicone 2 well culture-insert (Ibidi,
Martinsried, Germany) that patterns cells around an open gap. After cells grew to confluency (24 hr), the silicone insert was removed,
creating a gap (wound), into which cells migrated. The dishes were replenished with DMEM media containing high glucose buffer
(GIBCO, Life Technologies), 10% FBS, 20 mM L-glutamine, and 1 mM sodium pyruvate. Wound closure was monitored at 10 min
intervals for 16 hr, maintaining cells at 37Cwith 5%CO2 using an Okolab controller adapted to the inverted Nikon Ti-E-PFS3 eclipse
microscope described above. Images were captured using a 10x (NA 0.3) air objective with a pixel size of 0.65 mm, and a Neo/Zyla
sCMOS camera (Andor Technology, Neo/Zyla sCMOS camera Melville, NY) using NIS element analysis software (version 4.20, Ni-
kon). Wound size and speed of wound closure were calculated using Wound Healing Automated Cellular Analysis System (ACAS)
web-based quantitative image analysis from MetaVi Labs/Ibidi (https://www.metavilabs.com/; Cat# 32000-250). Data were com-
bined from time-lapse image series collected from at least three independent experiments. Individual cells migrating at the edge
of the wound were tracked, and their trajectories were obtained using the Chemotaxis and Migration Tool version 2.0 software (Ibidi,
Germany).
For chemotaxis assays, MDA-MB-231 cells were grown on 6-well plates, then transfected with siRNA oligos and/or plasmids as
described. Tomake cells responsive to the chemotractant gradient, the DMEMmediumwas replaced by serum-free growth medium
UltraCULTURE TM (UC; Lonza) 24 hr after transfection. Then, adaptation was achieved in stepwise fashion, by replacing 20% of the
serum-containing basemediumwith serum-free medium each of three times. Next, the adapted cells were replated on a Collagen-IV
Chemotaxis m-slide (Ibidi) according to manufacturer’s protocol, and kept at 37Cwith 5% CO2. A chemotactic gradient of FBS was
established by placing media containing 0% FBS in the left reservoir, andmedia containing 10% FBS in the right reservoir of themid-
dle chamber containing the cells. The assay was repeated independently at least two times using different chambers. Cells were
maintained at 37C on an Ibidi heated stage, and migration was monitored at 2 min intervals for 10 hr using the inverted Nikon Ti-
E-PFS3 eclipse microscope described above. Images were captured using a 10x (NA 0.3) air objective with a pixel size of
0.65 mm, and a Neo/Zyla sCMOS camera (Andor Technology) using NIS element analysis software (version 4.20, Nikon). For each
condition, at least 900 individual cells were tracked using FastTrack Artificial Intelligence (AI) automated analysis system, an artificial
intelligence-based vision system from MetaVi Labs/Ibidi (Cat# 32200-3). The AI analysis system was iteratively trained to achieve
accurate tracking for 100% of the cells in these experiments. All trajectories from cells moving at least 50 mm in 8 hr were analyzed.
Data were combined from time-lapse image series collected from three independent experiments per condition. Parameters such asCurrent Biology 30, 1–10.e1–e8, December 7, 2020 e7
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Reportvelocity, directionality index, and Euclidean distance accumulated (indicative of how straight cells move), were extracted from the
track data. Trajectories were graphed as Rose plots using the Chemotaxis and Migration Tool version 2.0 software (Ibidi, Germany).
Statistical analysis was performed with GraphPad Prism 6.0.
QUANTIFICATION AND STATISTICAL ANALYSIS
All experiments were repeated multiple times, as indicated in the figure legends. In each case, the data were pooled, averaged, and
SD or SEM was calculated using GraphPad Prism (version 6.0c; GraphPad Software, La Jolla, CA). Figure legends specify the n and
the error bars (SD or SEM) for each experiment. Data distributions were tested for normality using D’Agostino-Pearson omnibus
normality test, and statistical significance of differences among conditions were calculated using ordinary one-way ANOVA Holm-
Sidak’s multiple comparisons tests in Prism software version 6.0c (GraphPad Software, La Jolla, CA). Differences were considered
significant if P value < 0.05 (*), < 0.01(**), < 0.001(***), or < 0.0001 (****), as indicated in each figure legend.e8 Current Biology 30, 1–10.e1–e8, December 7, 2020
